1. Home
  2. RYOJ vs GRDX Comparison

RYOJ vs GRDX Comparison

Compare RYOJ & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo rYojbaba Co. Ltd.

RYOJ

rYojbaba Co. Ltd.

N/A

Current Price

$2.59

Market Cap

29.1M

ML Signal

N/A

Logo GridAI Technologies Corp.

GRDX

GridAI Technologies Corp.

N/A

Current Price

$4.99

Market Cap

28.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RYOJ
GRDX
Founded
2015
N/A
Country
Japan
United Kingdom
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
29.1M
28.6M
IPO Year
2024
2016

Fundamental Metrics

Financial Performance
Metric
RYOJ
GRDX
Price
$2.59
$4.99
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 121.8K
107.9K
Earning Date
12-19-2026
11-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 21.95
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$19.04
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.56
$1.87
52 Week High
$8.10
$6.93

Technical Indicators

Market Signals
Indicator
RYOJ
GRDX
Relative Strength Index (RSI) 41.93 54.68
Support Level $1.95 $2.37
Resistance Level $2.78 $5.04
Average True Range (ATR) 0.46 0.58
MACD 0.07 0.03
Stochastic Oscillator 17.64 44.09

Price Performance

Historical Comparison
RYOJ
GRDX

About RYOJ rYojbaba Co. Ltd.

rYojbaba Co Ltd is engaged in improving and restoring physical and mental health diminished by work-related stress through consulting and health services. The company provides consulting services to labor unions and companies wishing to build constructive relationships with labor unions and health services to osteopathic clinics and osteopathic beauty salons to alleviate physical ailments created by work-related stress.

About GRDX GridAI Technologies Corp.

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: